Indoximod
Indoximod is in phase II clinical trials by NewLink Genetics for the treatment of breast cancer, prostate cancer, malignant brain tumor, pancreatic cancer, melanoma.
General Information
Update Date：2015-09-30
- Drug Name：
- Indoximod
- Research Code：
- NSC-721782; D-1MT; NLG-8189
- Trade Name：
- MOA：
- indoleamine 2
- Indication：
- Breast cancer; Prostate cancer; Malignant brain tumor; Pancreatic cancer; Melanoma
- Status：
- Phase II (Active)
- Company：
- NewLink Genetics (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-09-30
|
Molecular Weight | 218.25 | ||||||||||||
| Formula | C12H14N2O2 | |||||||||||||
| CAS No. | 110117-83-4 (Indoximod); | |||||||||||||
| Chemical Name | D-Tryptophan, 1-methyl- | |||||||||||||
| Indoximod （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||